Literature DB >> 3808914

Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Y A Hekster, T B Vree, C M Weemaes, J J Rotteveel.   

Abstract

The use of vancomycin is rapidly increasing due to the emergence of strains of staphylococci resistant to betalactam antibiotics. In this communication the pharmacokinetics of an overdose of vancomycin in a patient during continuous ambulatory peritoneal dialysis (CAPD) is reported. Brainstem auditory evoked potentials (BAEPs) are used to assess ototoxicity. It could be shown that by shortening the dwell time, the apparent CAPD flow was increased and the vancomycin clearance was also increased. This may explain in part the differences in the values of vancomycin t1/2 in this patient (21 h) as compared to other studies (60-120 h). The age of the patient (3.5 years) may also have influenced the t1/2. Using brainstem auditory evoked potentials as a parameter to assess ototoxicity, it was shown that this patient suffered no damage from the overdose.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3808914     DOI: 10.1007/bf02280053

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  19 in total

1.  The central auditory conduction at term date and three months after birth. II. Auditory brainstem response.

Authors:  J J Rotteveel; E J Colon; S L Notermans; G B Stoelinga; Y Visco; R de Graaf
Journal:  Scand Audiol       Date:  1986

2.  The inadequacy of click-evoked auditory brainstem responses in audiological applications.

Authors:  J J Eggermont
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

3.  Multisensory evoked potentials in experimental and applied neurotoxicology.

Authors:  C S Rebert
Journal:  Neurobehav Toxicol Teratol       Date:  1983 Nov-Dec

4.  Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis.

Authors:  B E Magera; J C Arroyo; S J Rosansky; B Postic
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

5.  Clinical pharmacology and efficacy of vancomycin in pediatric patients.

Authors:  U B Schaad; G H McCracken; J D Nelson
Journal:  J Pediatr       Date:  1980-01       Impact factor: 4.406

6.  Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transport.

Authors:  M C Rogge; C A Johnson; S W Zimmerman; P G Welling
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Vancomycin kinetics during continuous ambulatory peritoneal dialysis.

Authors:  C M Bunke; G R Aronoff; M E Brier; R S Sloan; F C Luft
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

8.  Ototoxicity of oral neomycin and vancomycin.

Authors:  K T Kavanagh; B F McCabe
Journal:  Laryngoscope       Date:  1983-05       Impact factor: 3.325

9.  Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis.

Authors:  M E McIntosh; W G Smith; B J Junor; G Forrest; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 10.  Vancomycin therapy of severe staphylococcal infections.

Authors:  W M Kirby
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

View more
  3 in total

1.  Pharmacokinetics of theophylline and its metabolites in a patient undergoing continuous ambulatory peritoneal dialysis.

Authors:  T B Vree; M Martea; R G Tiggeler; Y A Hekster; J C Hafkenscheid
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 2.  Vancomycin ototoxicity and nephrotoxicity. A review.

Authors:  G R Bailie; D Neal
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

3.  Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.

Authors:  M Martea; Y A Hekster; T B Vree; A J Voets; J H Berden
Journal:  Pharm Weekbl Sci       Date:  1987-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.